Literature DB >> 8687515

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.

J E Nestler1, D J Jakubowicz.   

Abstract

BACKGROUND: Insulin resistance and increased ovarian cytochrome P450c17 alpha activity are both features of the polycystic ovary syndrome. P450c17 alpha, which is involved in androgen biosynthesis, has both 17 alpha-hydroxylase and 17,20-lyase activities. Increased activity of this enzyme results in exaggerated conversion of progesterone to 17 alpha-hydroxyprogesterone in response to stimulation by gonadotrophin. We hypothesized that hyperinsulinemia stimulates ovarian P450c17 alpha activity.
METHODS: We measured fasting serum steroid concentrations and the response of serum 17 alpha-hydroxyprogesterone to leuprolide, a gonadotrophin-releasing hormone agonist, and performed oral glucose-tolerance tests before and after oral administration of either metformin (500 mg three times daily) or placebo for four to eight weeks in 24 obese women with the polycystic ovary syndrome.
RESULTS: In the 11 women given metformin, the mean (+/- SE) area under the serum insulin curve after oral glucose administration decreased from 9303 +/- 1603 to 4982 +/- 911 microU per milliliter per minute (56 +/- 10 to 30 +/- 6 nmol per liter per minute) (P = 0.004). This decrease was associated with a reduction in the basal serum 17 alpha-hydroxyprogesterone concentration from 135 +/- 21 to 66 +/- 7 ng per deciliter (4.1 +/- 0.6 to 2.0 +/- 0.2 nmol per liter) (P = 0.01) and a reduction in the leuprolide-stimulated peak serum 17 alpha-hydroxyprogesterone concentration from 455 +/- 54 to 281 +/- 52 ng per deciliter (13.7 +/- 1.6 to 8.5 +/- 1.6 nmol per liter) (P = 0.01). The serum 17 alpha-hydroxyprogesterone values increased slightly in the placebo group. In the metformin group, the basal serum luteinizing hormone concentration decreased from 8.5 +/- 2.2 to 2.8 +/- 0.5 mlU per milliliter (P = 0.01), the serum free testosterone concentration decreased from 0.34 +/- 0.07 to 0.19 +/- 0.05 ng per deciliter (12 +/- 3 to 7 +/- 2 pmol per liter) (P = 0.009), and the serum sex hormone-binding globulin concentration increased from 0.8 +/- 0.2 to 2.3 +/- 0.6 microgram per deciliter (29 +/- 7 to 80 +/- 21 nmol per liter) (P < 0.001). None of these values changed significantly in the placebo group.
CONCLUSIONS: In obese women with the polycystic ovary syndrome, decreasing serum insulin concentrations with metformin reduces ovarian cytochrome P450c17 alpha activity and ameliorates hyperandrogenism.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8687515     DOI: 10.1056/NEJM199608293350902

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  107 in total

Review 1.  The ovarian androgen-producing cells: a 2001 perspective.

Authors:  Denis A Magoffin
Journal:  Rev Endocr Metab Disord       Date:  2002-01       Impact factor: 6.514

2.  Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome.

Authors:  Susan Sam; David A Ehrmann
Journal:  Diabetologia       Date:  2017-08-03       Impact factor: 10.122

3.  Metformin during pregnancy in polycystic ovary syndrome: another vitamin bites the dust.

Authors:  Richard S Legro
Journal:  J Clin Endocrinol Metab       Date:  2010-12       Impact factor: 5.958

4.  Effects of low-dose metformin in Japanese women with clomiphene-resistant polycystic ovary syndrome.

Authors:  Takumi Kurabayashi; Mina Suzuki; Katsunori Kashima; Junichi Banzai; Kyoko Terabayashi; Kazuyuki Fujita; Kenichi Tanaka
Journal:  Reprod Med Biol       Date:  2004-03-30

Review 5.  Commentary: polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin?

Authors:  Jean-Patrice Baillargeon; John E Nestler
Journal:  J Clin Endocrinol Metab       Date:  2005-11-01       Impact factor: 5.958

Review 6.  Surgical treatment of obesity.

Authors:  Nancy Puzziferri; Jeanne Blankenship; Bruce M Wolfe
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

Review 7.  Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.

Authors:  Lara C Morley; Thomas Tang; Ephia Yasmin; Robert J Norman; Adam H Balen
Journal:  Cochrane Database Syst Rev       Date:  2017-11-29

Review 8.  Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology.

Authors:  Z E Hopkinson; N Sattar; R Fleming; I A Greer
Journal:  BMJ       Date:  1998-08-01

Review 9.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

10.  Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial.

Authors:  Vanita R Aroda; Theodore P Ciaraldi; Paivi Burke; Sunder Mudaliar; Paul Clopton; Susan Phillips; R Jeffrey Chang; Robert R Henry
Journal:  J Clin Endocrinol Metab       Date:  2008-11-04       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.